Home > Newsletters > FDAnews Drug Daily Bulletin > EMA Plans to Update Guidance on Trials for Cancer Drugs
FDAnews Drug Daily Bulletin
Oct. 12, 2010 | Vol. 7 No. 199
EMA Plans to Update Guidance on Trials for Cancer Drugs
Noting that roughly a third of new chemical and biological entities in clinical development are anti-cancer treatments, the European Medicines Agency (EMA) may update its guideline on trials for anti-cancer drugs. The revision would harmonize the main guideline, which was last revised in 2006, with more recent appendices related to progression-free survival, blood-related malignancies and pediatric studies, according to a recently released consultation paper.
Clinical Trials Advisor
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.